Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-06-27
2004-02-03
Leffers, Jr., Gerald G. (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S006120, C424S190100, C424S009362, C424S184100, C436S501000, C436S517000, C436S518000, C436S536000, C530S300000, C530S350000, C536S023100
Reexamination Certificate
active
06686166
ABSTRACT:
Tuberculosis is an ancient human scourge that continues to be an important public health problem worldwide. It is an ongoing epidemic of staggering proportions. Approximately one in every three people in the world is infected with
Mycobacterium tuberculosis
, and has a 10% lifetime risk of progressing from infection to clinical disease. Although tuberculosis can be treated, an estimated 2.9 million people died from the disease last year.
There are significant problems with a reliance on drug treatment to control active
M. tuberculosis
infections. Most of the regions having high infection rates are less developed countries, which suffer from a lack of easily accessible health services, diagnostic facilities and suitable antibiotics against
M. tuberculosis
. Even where these are available, patient compliance is often poor because of the lengthy regimen required for complete treatment, and multidrug-resistant strains are increasingly common.
Prevention of infection would circumvent the problems of treatment, and so vaccination against tuberculosis is widely performed in endemic regions. Around 100 million people a year are vaccinated with live bacillus Calmette-Guerin (BCG) vaccine. BCG has the great advantage of being inexpensive and easily administered under less than optimal circumstances, with few adverse reactions. Unfortunately, the vaccine is widely variable in its efficacy, providing anywhere from 0 to 80% protection against infection with
M. tuberculosis.
BCG has an interesting history. It is an attenuated strain of
M. bovis
, a very close relative of
M. tuberculosis
. The
M. bovis
strain that became BCG was isolated from a cow in the late 1800's by a bacteriologist named Nocard, hence it was called Nocard's bacillus. The attenuation of Nocard's bacillus took place from 1908 to 1921, over the course of 230 in vitro passages. Thereafter, it was widely grown throughout the world, resulting in additional hundreds and sometime thousands of in vitro passages. Throughout its many years in the laboratory, there has been selection for cross-reaction with the tuberculin skin test, and for decreased side effects. The net results have been a substantially weakened pathogen, which may be ineffective in raising an adequate immune response.
New antituberculosis vaccines are urgently needed for the general population in endemic regions, for HIV-infected individuals, as well as health care professionals likely to be exposed to tubercle bacilli. Recombinant DNA vaccines bearing protective genes from virulent
M. tuberculosis
are being developed using shuttle plasmids to transfer genetic material from one mycobacterial species to another, for example see U.S. Pat. No. 5,776,465. Tuberculosis vaccine development should be given a high priority in current medical research goals.
Relevant Literature
Mahairas et al. (1996)
J Bacteriol
178(5):1274-1282 provides a molecular analysis of genetic differences between
Mycobacterium bovis
BCG and virulent
M. bovis
. Subtractive genomic hybridization was used to identify genetic differences between virulent
M. bovis
and
M. tuberculosis
and avirulent BCG. U.S. Pat. No. 5,700,683 is directed to these genetic differences.
Cole et al. (1998)
Nature
393:537-544 have described the complete genome of
M. tuberculosis
. To obtain the contiguous genome sequence, a combined approach was used that involved the systematic sequence analysis of selected large-insert clones as well as random small-insert clones from a whole-genome shotgun library. This culminated in a composite sequence of U.S. Pat. No. 4,411,529 base pairs, with a G+C content of 65.6%. 3,924 open reading frames were identified in the genome, accounting for ~91% of the potential coding capacity.
Mycobacterium tuberculosis
(
M. tb
.) genomic sequence is available at several internet sites.
SUMMARY OF THE INVENTION
Genetic markers are provided that distinguish between strains of the
Mycobacterium tuberculosis
complex, particularly between avirulent and virulent strains. Strains of interest include
M. bovis, M. bovis
BCG strains,
M. tuberculosis
(
M. tb
.) isolates, and bacteriophages that infect mycobacteria. The genetic markers are used for assays, e.g. immunoassays, that distinguish between strains, such as to differentiate between BCG immunization and
M. tb
. infection. The protein products may be produced and used as an immunogen, in drug screening, etc. The markers are useful in constructing genetically modified
M. tb
. or
M. bovis
cells having improved vaccine characteristics.
REFERENCES:
patent: 5686597 (1997-11-01), Coleman et al.
patent: 5776465 (1998-07-01), O'Donnell et al.
patent: 5955356 (1999-09-01), Content et al.
patent: 6291190 (2001-09-01), Behr et al.
patent: WO 96/27129 (1996-02-01), None
patent: WO 96/25519 (1996-08-01), None
patent: WO 01/04151 (2001-01-01), None
Brosch et al. Infection and Immunity, May 1998, vol. 66, No. 5, pp. 2221-2229.*
Mahairas et al. Journal of Bacteriology, Mar. 1996, vol. 178, No. 5, pp. 1274-1282*
Cole, et al. Nature, Jun. 1998, vol. 393, pp. 537-544.*
Cole, et al. Nature, Nov. 1998, vol. 396, Errata, pp. 190-198.*
Gordon et al. Molecular Microbiology, Apr. 1999, vol. 32, No. 3, pp. 643-655.*
Behr et al. Science, May 1999, vol. 284, pp. 1520-1523.*
Aldovini, et al., (1993)Journal of Bacteriology, vol. 175:7282-7289.
Converse, et al., (1996)Infection and Immunity, vol. 64, No. (11):4776-4787.
Delahunty, et al., (1996)American Journal of Human Genetics, vol. 58:1239-1246.
DeRisi, et al., (1996)Nature Genetics, vol. 14:457-460.
Ganjam, et al., (1991),P.N.A.S., vol. 88:5433-5437.
Hacia, et al., (1996)Nature Genetics, vol. 14:441-447.
Jost, et al., (1994)Journal of Biochemistry, vol. 269:26267-73.
Lockhart, et al., (1996)Nature Biotechnology, vol. 14:1675-1680.
Norman, et al., (1995)Molecular Microbiology, vol. 16:755-760.
Paul, et al., (1996)journal of Infectious Diseases, vol. 174, No. (1):105-112.
Philip, W. et al., (1996)Microbiology, vol. 142:3135-3145.
Ramsay, et al., (1998)Nature Biotechnology, vol. 16:40-44.
Riley, et al., (1990)Nucleic Acids Research, vol. 18:2887-2890.
Saiki, et al., (1985)Science, vol. 239:487-491.
Sambrook, et al.,Molecular Cloning: A Laboratory Manual, CSH Press(1989), pp:14.2-14.33.
Shalon, et al., (1996)Genome Research, vol. 6:639-645.
Silver, et al., (1998)Infection and Immunology, vol. 66, No. (3):1190-1199.
Talbot, et al., (1997)Journal of Clinical Microbiology, vol. 35:566-569.
Behr Marcel
Schoolnik Gary
Small Peter
Wilson Michael A.
Bozicevic Field & Francis LLP
Leffers, Jr. Gerald G.
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Molecular differences between species of the M. tuberculosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular differences between species of the M. tuberculosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular differences between species of the M. tuberculosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3315707